Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases

• Published in: Seminars in arthritis and rheumatism Vol. 48; no. 6; pp. 1083 - 1086
• Main Authors: Etminan, Mahyar, Sodhi, Mohit, Samii, Ali, Carleton, Bruce C, Kezouh, Abbas, Antonio Avina-Zubieta, J
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2019
• Subjects: Adult; Aged; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Case-Control Studies; Databases, Factual; Female; Humans; Incidence; Male; Middle Aged; Nested case-control study; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - epidemiology; Peripheral neuropathy; Rheumatic Diseases - drug therapy; Risk; Tumor necrosis factor inhibitors; Tumor Necrosis Factor Inhibitors - adverse effects; Tumor Necrosis Factor Inhibitors - therapeutic use; United States; United States; Peripheral neuropathy; Nested case-control study; Tumor necrosis factor inhibitors

Tumor necrosis factor inhibitors (TNFi) are widely used in the treatment of a variety of autoimmune diseases. A number of case reports have linked TNFi to neurologic adverse events including peripheral neuropathy (PN) in patients with rheumatic diseases. To quantify the risk of peripheral neuropathy...